Overview

Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
Recent evidence suggests multiple drug therapy is superior to single agents. The study compares the incidence of nausea, vomiting, need for rescue medication, prolonged PACU time, and unplanned hospital admission in patients with high risk for PONV treated with oral aprepitant with or without transdermal scopolamine preoperatively.
Phase:
N/A
Details
Lead Sponsor:
Drexel University College of Medicine
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Aprepitant
Butylscopolammonium Bromide
Fosaprepitant
Scopolamine
Scopolamine Hydrobromide